Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 1/2 1

Status

Completed 14Recruiting 13Unknown 8Withdrawn 4Terminated 4Not yet recruiting 2Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 2Leukemia, Prolymphocytic, T-Cell 1

Interventions

venetoclax 26Azacitidine 24fludarabine 11Cytarabine 11Specimen Handling 9Biopsy 7Busulfan 6Melphalan 5Decitabine 5Daunorubicin 5Thiotepa 4Cyclophosphamide 4selinexor 3olutasidenib 3gilteritinib 3Whole-Body Irradiation 3Tacrolimus 3Idarubicin 3Homoharringtonine 3treosulfan 2revumenib 2fludarabine phosphate 2decitabine and cedazuridine drug combination 2Stem Cell Transplantation 2Maintenance 2Lymphatic Irradiation 2Leukapheresis 2Injections 2Granulocyte Colony-Stimulating Factor 2Drug Therapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Leukemia, Myeloid, Acute × Cladribine × Clear all
NCT07053020 2026-03-04

A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)

M.D. Anderson Cancer Center

Phase 1/2 Not yet recruiting
58 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06763666 2025-01-08

CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML

Nanfang Hospital, Southern Medical University

Phase 4 Not yet recruiting
172 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡